NASDAQ:POAI - Nasdaq - US74039M3097 - Common Stock - Currency: USD
PREDICTIVE ONCOLOGY INC
NASDAQ:POAI (2/10/2025, 8:18:24 PM)
1.43
-0.02 (-1.38%)
The current stock price of POAI is 1.43 USD. In the past month the price increased by 5.15%. In the past year, price decreased by -56%.
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session.
Study used Predictive Oncology’s vast biobank of cryopreserved live cell tumor specimens for the production and testing of primary patient tumor spheroids ...
Initial plans target European clinical trials while providing standard testing to clinicians for individual patients There are an estimated 250,000...
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 28.12 | 227.75B | ||
ISRG | INTUITIVE SURGICAL INC | 81.27 | 212.18B | ||
BSX | BOSTON SCIENTIFIC CORP | 42.3 | 156.49B | ||
SYK | STRYKER CORP | 32.21 | 149.67B | ||
MDT | MEDTRONIC PLC | 17.3 | 116.48B | ||
BDX | BECTON DICKINSON AND CO | 17.44 | 66.57B | ||
EW | EDWARDS LIFESCIENCES CORP | 26.63 | 41.93B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 20.73 | 39.98B | ||
IDXX | IDEXX LABORATORIES INC | 41.33 | 38.07B | ||
RMD | RESMED INC | 26.99 | 35.02B | ||
DXCM | DEXCOM INC | 51.92 | 34.48B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 20.74 | 25.93B |
Predictive Oncology, Inc. engages in the application of artificial intelligence medicine business and provision of cleared STREAMWAY System for automated, direct-to-drain medical fluid disposal, and associated products. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 34 full-time employees. The company went IPO on 2009-12-18. The firm operates through three segments: Pittsburgh, Birmingham, and Eagan. Pittsburgh segment provides services, which include the application of artificial intelligence (AI) using its proprietary biobank of 150,000 plus tumor samples. Pittsburgh segment also develops tumor-specific in vitro models for oncology drug discovery and research. Birmingham segment focuses on contract services and research for biopharmaceutical company clients and academic collaborators, focused on solubility improvements, stability studies, and protein production. Specifically, Birmingham provides optimized formulations for vaccines, antibodies, and other protein therapeutics. Eagan segment produces the STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal.
PREDICTIVE ONCOLOGY INC
91 43Rd Street, Suite 110
Pittsburgh PENNSYLVANIA 55121 US
CEO: Carl Schwartz
Employees: 35
Company Website: https://predictive-oncology.com/
Investor Relations: http://investors.predictive-oncology.com
Phone: 14124321500
The current stock price of POAI is 1.43 USD.
The exchange symbol of PREDICTIVE ONCOLOGY INC is POAI and it is listed on the Nasdaq exchange.
POAI stock is listed on the Nasdaq exchange.
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for POAI, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of POAI.
POAI does not pay a dividend.
POAI does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.06).
The outstanding short interest for POAI is 6.98% of its float.
ChartMill assigns a technical rating of 9 / 10 to POAI. When comparing the yearly performance of all stocks, POAI is one of the better performing stocks in the market, outperforming 86.57% of all stocks.
ChartMill assigns a fundamental rating of 1 / 10 to POAI. Both the profitability and financial health of POAI have multiple concerns.
Over the last trailing twelve months POAI reported a non-GAAP Earnings per Share(EPS) of -3.06. The EPS increased by 34% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -186.31% | ||
ROE | -710.24% | ||
Debt/Equity | 0.1 |
ChartMill assigns a Buy % Consensus number of 43% to POAI. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of -1633.33% and a revenue growth -90.58% for POAI